Evidence map›Paper›PMID 40806210›Full record

ArticleInternational journal of molecular sciences2025

Multiomics Signature Reveals Network Regulatory Mechanisms in a CRC Continuum.

Juan Carlos Higareda-Almaraz, Francesco Mattia Mancuso, Pol Canal-Noguer, Kristi Kruusmaa, Arianna Bertossi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juan Carlos Higareda-AlmarazUniversal Diagnostics S.A., 41013 Seville, Spain.ORCID 0000-0002-4043-8547
Francesco Mattia MancusoUniversal Diagnostics S.A., 41013 Seville, Spain.ORCID 0000-0001-5499-6630
Pol Canal-NoguerUniversal Diagnostics S.A., 41013 Seville, Spain.
Kristi KruusmaaResearch & Development, Universal Diagnostics d.o.o., 1000 Ljubljana, Slovenia.ORCID 0000-0001-5498-6125
Arianna BertossiResearch & Development, Universal Diagnostics d.o.o., 1000 Ljubljana, Slovenia.ORCID 0000-0001-6088-7318

Funding

Universal Diagnostics S.A.
6 · The paper itself

Abstract

Sporadic colorectal cancer (CRC), the third leading cause of cancer-related death globally, arises through a continuum from normal tissue to adenomas, progressing from low-grade (LGD) to high-grade dysplasia (HGD); yet, the early epigenetic drivers of this transition remain unclear. To investigate these events, we profiled LGD and HGD adenomas using EM-seq, and identified a consensus differential methylation signature (DMS) of 626 regions through two independent bioinformatics pipelines. This signature effectively distinguished LGD from HGD in both tissue and plasma-derived cell-free DNA (cfDNA), highlighting specific methylation patterns. Functional annotation indicated enrichment for regulatory elements associated with transcription factor activity and cell signaling. Applying the DMS to the TCGA CRC dataset revealed three tumor subtypes with increasing hypermethylation and one normal cluster. The most hypermethylated subtype exhibited poor survival, high mutation burden, and disrupted transcriptional networks. While overlapping with classical CpG Island Methylator Phenotype (CIMP) categories, the DMS captured a broader spectrum of methylation alterations. These findings suggest that the DMS captures functionally relevant, antecedent epigenetic alterations in CRC progression, enabling the robust stratification of dysplasia severity and tumor subtypes. This signature holds promise for enhancing preclinical detection and molecular classification, and warrants further evaluation in larger prospective cohorts.

Indexed as

Colorectal NeoplasmsGene Expression Regulation, NeoplasticGene Regulatory NetworksAdenomaCpG IslandsDNA MethylationEpigenesis, GeneticFemaleGene Expression ProfilingHumansMaleMultiomicsadvanced adenomascolorectal cancerearly detectionhigh-grade dysplasialow-grade dysplasiamethylationmultiomicsregulatory network

Identifiers

PMID40806210
PMCPMC12346659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.